Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Mark Pomerantz, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Physician
  • Assistant Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Genetics
  • Prostate cancer
  • Testicular cancer

Contact Information

  • Appointments877-332-4294 (new)
    617-582-9725 (follow-up)
  • Office Phone Number617-632-4524
  • Fax617-632-2165

Bio

Dr. Mark Pomerantz is a medical oncologist at the Dana-Farber Cancer Institute. Dr. Pomerantz received his undergraduate degree from Yale University and his medical degree from Stanford University. He trained in Internal Medicine at Brigham and Women's Hospital in Boston, Massachusetts. He then pursued a fellowship in Medical Oncology at the Dana-Farber Cancer Institute in Boston. Dr. Pomerantz received his post-doctroal training in cancer genetics with Dr. Matthew Freedman at the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT. He is on faculty at the Dana-Farber Cancer Institute in the Lank Center for Genitourinary Oncology.

Board Certification:

  • Internal Medicine, 2004
  • Medical Oncology, 2007

Fellowship:

  • Dana-Farber/Partners CancerCare, Hematology/Oncology

Residency:

  • Brigham and Women's Hospital, Internal Medicine

Medical School:

  • Stanford University School of Medicine

Research

Inherited risk of cancer and genetic determinants disease outcome

Dr. Pomerantz's research focuses on the factors associated with cancer risk, with an emphasis on prostate cancer. Prostate cancer develops in the setting of many environmental and inherited risk factors. Since 2006, the inherited component of the disease has come into clearer focus. Multiple genetic markers, inherited from one's parents and highly associated with risk of prostate cancer, have been discovered. However, the mechanism in which these inherited factors predispose one to disease is unknown. Working closely with clinicians, biostatisticians and epidemiologists at Dana-Farber and the Broad Institute, he is actively deciphering this mechanism in an attempt to define the underpinnings of prostate cancer risk. 

A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Prostate. 2021 Jul; 81(10):683-693.
View in: PubMed

Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer. J Natl Cancer Inst. 2021 May 04; 113(5):616-625.
View in: PubMed

Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Rep. 2021 Mar 30; 34(13):108926.
View in: PubMed

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun. 2021 03 30; 12(1):1979.
View in: PubMed

EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021 Apr; 2(4):444-456.
View in: PubMed

Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. J Urol. 2021 07; 206(1):80-87.
View in: PubMed

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808.
View in: PubMed

Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. Mol Cancer Res. 2021 03; 19(3):475-484.
View in: PubMed

Author Correction: Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 Oct; 26(10):1663.
View in: PubMed

Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clin Cancer Res. 2020 12 01; 26(23):6122-6131.
View in: PubMed

Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet. 2020 08; 52(8):790-799.
View in: PubMed

Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 07; 26(7):1041-1043.
View in: PubMed

Correction: Evaluation of significant genome-wide association studies risk-SNPs in young breast cancer patients. PLoS One. 2020; 15(3):e0230529.
View in: PubMed

Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations. Clin Cancer Res. 2020 06 01; 26(11):2673-2680.
View in: PubMed

Allele-Specific QTL Fine Mapping with PLASMA. Am J Hum Genet. 2020 02 06; 106(2):170-187.
View in: PubMed

A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. Br J Cancer. 2020 02; 122(4):555-563.
View in: PubMed

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020 02 01; 80(3):624-638.
View in: PubMed

Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nat Med. 2019 10; 25(10):1615-1626.
View in: PubMed

CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. Cancer Discov. 2019 11; 9(11):1538-1555.
View in: PubMed

Sex specific associations in genome wide association analysis of renal cell carcinoma. Eur J Hum Genet. 2019 10; 27(10):1589-1598.
View in: PubMed

Evaluation of significant genome-wide association studies risk - SNPs in young breast cancer patients. PLoS One. 2019; 14(5):e0216997.
View in: PubMed

Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. J Med Internet Res. 2019 05 02; 21(5):e12044.
View in: PubMed

A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019 07 15; 25(14):4480-4492.
View in: PubMed

Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur Urol. 2020 01; 77(1):3-10.
View in: PubMed

Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. Brachytherapy. 2019 Mar - Apr; 18(2):198-203.
View in: PubMed

The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. PLoS Med. 2019 01; 16(1):e1002724.
View in: PubMed

A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer. 2019 02 15; 125(4):524-532.
View in: PubMed

Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. Eur Urol Oncol. 2019 09; 2(5):475-482.
View in: PubMed

Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival. Prostate. 2019 01; 79(1):73-80.
View in: PubMed

Implementation to Optimization: A Tailored, Data-Driven Approach to Improve Provider Efficiency and Confidence in Use of the Electronic Medical Record. J Oncol Pract. 2018 07; 14(7):e421-e428.
View in: PubMed

A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell. 2018 07 12; 174(2):422-432.e13.
View in: PubMed

A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate. 2018 Jun 07.
View in: PubMed

Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clin Cancer Res. 2018 09 01; 24(17):4081-4088.
View in: PubMed

Corrigendum re "Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma" [Eur Urol 2017;72:747-54]. Eur Urol. 2018 09; 74(3):e85-e86.
View in: PubMed

Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precis Oncol. 2018; 2.
View in: PubMed

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):883-888.
View in: PubMed

Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer. JAMA Oncol. 2018 Apr 01; 4(4):558-562.
View in: PubMed

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA. 2018 03 06; 319(9):896-905.
View in: PubMed

Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. Eur Urol. 2017 11; 72(5):747-754.
View in: PubMed

The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May; 77(13):1303-1311.
View in: PubMed

The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017 Sep 15; 123(18):3532-3539.
View in: PubMed

Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nat Commun. 2017 06 09; 8:15724.
View in: PubMed

Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet. 2016 10; 48(10):1142-50.
View in: PubMed

A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer. Prostate. 2016 10; 76(14):1338-41.
View in: PubMed

Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2016 Dec 15; 2(6):633-639.
View in: PubMed

Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat Commun. 2016 Apr 07; 7:10979.
View in: PubMed

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 08; 14(4):e299-305.
View in: PubMed

Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. J Clin Oncol. 2016 Feb 01; 34(4):352-9.
View in: PubMed

Active Surveillance: Pathologic and Clinical Variables Associated with Outcome. Surg Pathol Clin. 2015 Dec; 8(4):581-5.
View in: PubMed

Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Cancer. 2016 Feb 01; 122(3):402-10.
View in: PubMed

The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015 Nov; 47(11):1346-51.
View in: PubMed

CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants. Nat Med. 2015 Nov; 21(11):1357-63.
View in: PubMed

Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85.
View in: PubMed

Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Hum Mol Genet. 2015 Oct 01; 24(19):5603-18.
View in: PubMed

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. JAMA Oncol. 2015 Jul; 1(4):495-504.
View in: PubMed

Sequencing current therapies in the treatment of metastatic prostate cancer. Cancer Treat Rev. 2015 Apr; 41(4):332-40.
View in: PubMed

Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Hum Genet. 2015 Apr; 134(4):439-50.
View in: PubMed

Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. J Urol. 2015 Jul; 194(1):91-7.
View in: PubMed

Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer. 2013 Aug 15; 119(16):2990-8.
View in: PubMed

Clinical uncertainty of prostate cancer genetic risk panels. Sci Transl Med. 2013 Apr 24; 5(182):182ed6.
View in: PubMed

Association of Gleason 9-10 prostate cancer with worse outcomes compared to Gleason 8 disease. J Clin Oncol. 2013 Feb 20; 31(6_suppl):157.
View in: PubMed

Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis. J Clin Oncol. 2013 Feb 20; 31(6_suppl):33.
View in: PubMed

Renal-cell carcinoma: a step closer to a new classification. Lancet Oncol. 2013 Feb; 14(2):105-7.
View in: PubMed

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol. 2013 Jan; 14(1):81-7.
View in: PubMed

Moving toward personalized medicine in castration-resistant prostate cancer. Urol Clin North Am. 2012 Nov; 39(4):483-90.
View in: PubMed

Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A. 2012 Jul 10; 109(28):11252-7.
View in: PubMed

The role of genetic markers in the management of prostate cancer. Eur Urol. 2012 Oct; 62(4):577-87.
View in: PubMed

The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate. 2012 Jul 01; 72(10):1093-103.
View in: PubMed

The genetics of cancer risk. Cancer J. 2011 Nov-Dec; 17(6):416-22.
View in: PubMed

The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res (Phila). 2011 Dec; 4(12):2044-50.
View in: PubMed

SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20; 29(18):2565-73.
View in: PubMed

Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study. J Clin Oncol. 2011 May 20; 29(15_suppl):4506.
View in: PubMed

Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila). 2011 May; 4(5):719-28.
View in: PubMed

Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res. 2011 Mar 15; 17(6):1546-52.
View in: PubMed

Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204.
View in: PubMed

Genetics of prostate cancer risk. Mt Sinai J Med. 2010 Nov-Dec; 77(6):643-54.
View in: PubMed

Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res. 2010 Nov 01; 16(21):5244-51.
View in: PubMed

Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev. 2010 Jul; 19(7):1871-8.
View in: PubMed

8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A. 2010 May 25; 107(21):9742-6.
View in: PubMed

Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiol Biomarkers Prev. 2010 Jan; 19(1):1-8.
View in: PubMed

Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 2009 Aug; 5(8):e1000597.
View in: PubMed

The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet. 2009 Aug; 41(8):882-4.
View in: PubMed

Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 01; 69(13):5568-74.
View in: PubMed

Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 01; 15(9):3223-30.
View in: PubMed

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009 Mar 01; 115(5):981-7.
View in: PubMed

Quantitative gene expression at the 8q24 prostate cancer risk locus. J Clin Oncol. 2008 May 20; 26(15_suppl):5055.
View in: PubMed

Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008 Mar 15; 112(6):1247-53.
View in: PubMed

Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20; 26(6):842-7.
View in: PubMed

Genetic determinants of prostate cancer risk. BJU Int. 2007 Aug; 100(2):241-3.
View in: PubMed

Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007 Jun; 177(6):2146-50.
View in: PubMed

Phase II study of low dose and high dose premarin in androgen independent prostate cancer. Journal of Urology. 2007.

Advances in the treatment of prostate cancer. Annu Rev Med. 2007; 58:205-20.
View in: PubMed

Genetic polymorphisms in genes responsible for androgen metabolism are associated with time to prostate specific antigen progression (PSA-TTP) on primary androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer (HSCaP). Proc American Society of Clinical Oncology Prostate. 2007.

Diagnosis and treatment of low-grade prostate cancer. Hospital Physician. 2007.

Quantitation of estrogens in male plasma using liquid chromatography with an electrochemical detector. American Chemical Society. 2007.

Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). J Clin Oncol. 2006 Jun 20; 24(18_suppl):4560.
View in: PubMed

Genetics and inherited prostate cancer risk. Contemporary Urology. 2006; 18-25.

Phase II study of low dose and high dose premarin in androgen independent prostate cancer. Proc American Society of Clinical Oncology. 2006.

Is change in testosterone levels associated with an increase in prostate cancer risk? Results from the Massachusetts Male Aging Study (MMAS). Society for Epidemiologic Research. 2006.

Pulmonary resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg. 2001 Mar; 121(3):448-53.
View in: PubMed

Rectification of STM Current to Graphite Covered with Phthalocyanine Molecules. Science. 1992 Feb 28; 255(5048):1115-8.
View in: PubMed

Chronic pulmonary cavitation due to foreign body. JAMA. 1972 Feb; 219(6):742-3.
View in: PubMed

Chyluria with lymphangiographic abnormalities. JAMA. 1966 May 02; 196(5):452-4.
View in: PubMed

Dissecting aortic aneurysms. The role of fenestration procedures in treatment. Ann Thorac Surg. 1966 Mar; 2(2):150-8.
View in: PubMed

LYMPHANGIOGRAPHY: ITS USE IN THE DIAGNOSIS AND TREATMENT OF UROLOGIC DISORDERS. J Urol. 1964 Feb; 91:190-4.
View in: PubMed

THE EVALUATION OF CARBOCAINE AS A NEW LOCAL ANESTHETIC IN PODIATRY PROCEDURES. J Am Podiatry Assoc. 1963 Sep; 53:651-4.
View in: PubMed

Research Departments:

Support My Research

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1230
Boston, MA 02215
Get Directions

Ratings

Top